Boston Therapeutics' sugardown in clinical trials reduces glucose, fructose and insulin

sugardown reduces total glycemic index including fructose by up to 28% and insulin by up to 18%.

David Platt, CEO of Boston Therapeutics, said: "The clinical study results provide confirming support that sugardown can be effective in reducing glucose, (fructose by implication) and insulin response when consumed with sugary beverages. Sucrose and HFC, high fructose corn syrup, are a combination of glucose and fructose and preventing the breakdown is an important healthy diet management tool. The consumption of sugary soft drink beverages can lead to a wide range of health problems that through GI management can delay or reduce ill effects and poor health, including obesity, type 2 diabetes, fatty liver disease, high blood pressure, and even brain and cognitive disorders. All of which have been implicated in animal models. We will add the clinical data on sugardown's effects on sugary beverages as a section in our regulatory submissions. We believe these additional clinical data continue to be supportive of sugardown benefits as a dietary supplement classification. These clinical data will aid people with managing and reducing their overall systemic exposure to sugar after every meal."

sugardown in its present formulation is a natural sugar blocker dietary supplement product made entirely from an non-digestible sugar molecule that can help people maintain healthier weight levels and is the first chewable tablet of its kind. In a previous study, sugardown demonstrated significant reduction of glucose and insulin Area Under the Curve when taken with rice, a food with a 100% GI. Sugary soft drinks that also have high glycemic index, include sucrose and maltose which is also found in beer.